by Chris Black
You know that saying, the third time is the charm. The EU is rolling out the 3rd dose of Spikewax, even if there are numerous reports about side effects.
Finland will pause giving Moderna's Spikevax shots to men under the age of 30 due to the risk of heart inflammation t.co/2q9VcH4p8G
— Bloomberg (@business) October 7, 2021
Iceland is joining its Nordic peers in halting inoculations with Moderna’s Spikevax shot on concern over side effects t.co/MaaHnR5DvQ
— Bloomberg Africa (@BBGAfrica) October 8, 2021
"The connection [to inflammation of the heart] is especially clear when it comes to Moderna's vaccine Spikevax, especially after the second dose," the Swedish health agency said 💉
But they added that the risk of being affected was very small.
In full 👇t.co/3XvhNbObii
— Euronews Next (@euronewsnext) October 7, 2021
But who cares, right?
Moderna, Inc. announced that the European Medicines Agency (EMA) has authorized the third dose of its mRNA-based COVID-19 vaccine, Spikevax (mRNA-1273), for use in certain immunocompromised individuals aged 12 years or older. The additional dose needs to be administered after at least 28 days from the completion of the initial two-dose regimen.